Clinical Trials Logo

Clinical Trial Summary

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To collect, both prospectively and retrospectively, data on disease characterization, treatment, and outcomes for patients with neuroendocrine carcinoma of the uterine cervix. II. To organize clinical information in order to support multifaceted queries of patient characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with patient outcome. III. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research. OUTLINE: Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or United States (U.S.) mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually. ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Neuroendocrine
  • Carcinoma, Small Cell
  • Cervical Large Cell Neuroendocrine Carcinoma
  • Cervical Neuroendocrine Carcinoma
  • Cervical Small Cell Carcinoma
  • Cervical Undifferentiated Carcinoma
  • Small Cell Lung Carcinoma
  • Stage I Cervical Cancer AJCC v8
  • Stage IA Cervical Cancer AJCC v8
  • Stage IA1 Cervical Cancer AJCC v8
  • Stage IA2 Cervical Cancer AJCC v8
  • Stage IB Cervical Cancer AJCC v8
  • Stage IB1 Cervical Cancer AJCC v8
  • Stage IB2 Cervical Cancer AJCC v8
  • Stage II Cervical Cancer AJCC v8
  • Stage IIA Cervical Cancer AJCC v8
  • Stage IIA1 Cervical Cancer AJCC v8
  • Stage IIA2 Cervical Cancer AJCC v8
  • Stage IIB Cervical Cancer AJCC v8
  • Stage III Cervical Cancer AJCC v8
  • Stage IIIA Cervical Cancer AJCC v8
  • Stage IIIB Cervical Cancer AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Stage IVA Cervical Cancer AJCC v8
  • Stage IVB Cervical Cancer AJCC v8
  • Uterine Cervical Neoplasms

NCT number NCT04723095
Study type Observational
Source M.D. Anderson Cancer Center
Contact Michael M. Frumovitz
Phone 713-792-9599
Email nectur@mdanderson.org
Status Recruiting
Phase
Start date May 16, 2013
Completion date January 1, 2044

See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Active, not recruiting NCT03439085 - DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Completed NCT04269837 - Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer N/A
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03452332 - Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Phase 1
Active, not recruiting NCT03738228 - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Phase 1
Active, not recruiting NCT04501913 - Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Active, not recruiting NCT03634267 - MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer Phase 1